Welcome to our new CEO Chris Stevenson
Vox.Bio and Cambridge Healthcare Research are thrilled to announce the appointment of Chris Stevenson as chief executive officer. Chris transitions to this new role from his position on the board as a non-executive director.
Chris’ experience in change management and implementation spans periods leading organisations, reinvigorating distressed businesses and as a strategic consultant to the pharmaceutical industry. In the US, while at Thomson Reuters, he turned around three underperforming business units, was a member of the healthcare acquisitions team and became the in-house specialist in assessing professional services firms. He has also created a highly successful US operation for a medical communications agency, a novel EU operation for a US corporation and has consulted with various professional services firms across the healthcare sector. His brand experience includes the commercialisation and launch of anti-psychotic treatments globally for Johnson and Johnson, and commercial roles at BMS and GSK.
Having published numerous articles, mostly on the topics of strategic marketing and the leadership of professional services firms, Chris has a special interest in the growth and development of SMEs and has worked closely with a number of organisations in developing sustainable growth and people and leadership development programs. This appointment forms part of our strategic development milestones and in addition to organisational change, Chris will be helping increase the value of our offerings to new and existing clients.
And now a few words from our new CEO, Chris Stevenson:
“I am hugely excited to join Vox.Bio / CHR and the outstanding team we have. Over the past year I have learned a lot about the business, and there is a tremendous amount of potential. Winning the Queen’s Award for Enterprise [in international trade 2020] shows how well this company has been built and provides a great platform for future growth.”
Welcome to the team Chris!